-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Gastric Cancer Drug Details: PRS-343 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bersiporocin in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details: Bersiporocin (DWN-12088, DWJ-209) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Refractory Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Relapsed Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Triple-Negative Breast Cancer (TNBC) Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewNet Present Value Model: Prometheus Biosciences Inc’s PR-200
Empower your strategies with our Net Present Value Model: Prometheus Biosciences Inc's PR-200 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s PR-006
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's PR-006 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Automotive Steering Systems Market Trends, Sector Overview and Forecast to 2028
Automotive Steering Systems Market Report Overview The steering systems market size was 91 million units in 2023. The market will grow at a CAGR of more than 1% during 2023-2028. Continuous advancements in technology, such as improvements in electric power steering (EPS), sensors, and control algorithms drive the innovation of steering systems. In 2023, Asia-Pacific accounted for a significant share of the automotive steering systems market. Automotive Steering Systems Market Outlook, 2023-2028 (Million Units) Buy the Full Report for More...